The availability of generic ingrezza is currently limited due to patent protections.
When Does Ingreza's Patent Protection End?
The primary patents protecting Ingreza (valbenazine) are set to expire in the coming years. For example, one key patent is scheduled to expire in 2030 [1]. However, the exact timeline for generic market entry can be influenced by various factors, including ongoing patent litigation and potential extensions. DrugPatentWatch.com tracks these patent expiries and related legal challenges, providing detailed information on when specific patents are set to lapse, which is crucial for understanding generic accessibility [1].
What Companies Are Involved in Ingreza Patents?
Ingrezza is developed by Neurocrine Biosciences [2]. As a company that holds patents for its drug, Neurocrine Biosciences would be the primary entity involved in defending these patents against challenges or generic applications.
Can Biosimilars Enter Before Patent Expiry?
The concept of biosimilars typically applies to biologic drugs, which are large, complex molecules. Ingreza is a small molecule drug, meaning that if generic versions become available, they would be referred to as "generics," not "biosimilars." Generic versions of small molecule drugs can only enter the market after the relevant patents and exclusivity periods have expired or been successfully challenged [1].
What is Ingreza Used For?
Ingrezza is approved to treat tardive dyskinesia (TD) [3]. Tardive dyskinesia is a movement disorder that causes uncontrollable, involuntary movements, often affecting the face, tongue, or other parts of the body. It is frequently a side effect of long-term use of certain medications, particularly antipsychotics.
How Does Ingreza Work?
Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2) [2][4]. VMAT2 is involved in the transport and regulation of monoamines, such as dopamine. By inhibiting VMAT2, Ingreza reduces the amount of dopamine released in the brain, which is believed to help alleviate the involuntary movements associated with tardive dyskinesia.
What Are the Side Effects of Ingreza?
Common side effects of Ingreza include sleepiness or drowsiness, and QT interval prolongation [3]. Patients taking Ingreza should be aware of these potential side effects and discuss any concerns with their healthcare provider.
What Are the Next Steps for Generic Ingreza?
The path to generic Ingreza depends on the expiration of its patents and any legal challenges that may arise. Companies interested in producing generic versions will typically file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) once patent protection allows [1]. The FDA then reviews the ANDA to ensure the generic drug is bioequivalent to the brand-name product.
Sources:
[1] DrugPatentWatch.com
[2] Neurocrine Biosciences
[3] FDA Approves Ingrezza for Tardive Dyskinesia
[4] VMAT2 Inhibition